ixlayer adapts Covid-19 clinical testing platform

26 March 2020 (Last Updated March 26th, 2020 10:01)

ixlayer has adapted its platform to help laboratories and healthcare systems to address the demand for rapid and increased coronavirus (Covid-19) clinical testing.

ixlayer adapts Covid-19 clinical testing platform
ixlayer’s platform allows healthcare systems to quickly connect with partnering labs to deliver Covid-19 clinical testing. Credit: Fusion Medical Animation / Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.


ixlayer has adapted its platform to help laboratories and healthcare systems to address the demand for rapid and increased coronavirus (Covid-19) clinical testing.

The ixlayer Covid-19 clinical testing platform already encompasses the complex security components that are time-consuming to deliver.

It is now adapted for Covid-19 specific content and user flows, enabling clinicians to quickly connect with partnering labs to deliver clinical testing for the virus.

Furthermore, the platform can support multiple labs and providers across all states while allowing physicians to connect with patients remotely using its telemedicine infrastructure.

On the platform, patients can also directly request testing by logging into the secure patient portal and completing a health screening eligibility questionnaire, which evaluates their current symptoms, recent travel and community exposure to the disease.

ixlayer CEO Pouria Sanae said: “When the World Health Organization (WHO) declared rapid and global testing was needed to address Covid-19, I knew that would present challenges. Bringing a new test online can be complicated and time-consuming without technology solutions.

“Thankfully, the ixlayer platform has been efficiently delivering precision health testing across the US using the telehealth model for several years, so we already have the needed security and infrastructure in place.”

The Centers for Disease Control (CDC) and other researchers will be able to identify trends in disease transmission as ixlayer’s Covid-19 platform collects real-time data, including demographics on positive and negative tests by age, gender and geographic location.

In addition, issues with the testing pipeline can be identified and addressed immediately if a large number of inconclusive results are present in a given area.

ixlayer evaluates and adjusts the content in the platform regularly according to, CDC and WHO guidelines.

The content can be customised for the specific needs of individual groups while maintaining the integrity of the message from leading authorities.